|Articles|March 18, 2022

Top 5 Infectious Disease Stories of the Week-March 18, 2022

Check out these important stories we covered this past week.

Contagion compiles 5 highlights of our coverage in infectious disease including video interviews, podcasts, and significant stories from the week ending March 18, 2022

Here is an opportunity to catch-up with some of the important stories we have been covering this week.

Here are Contagion’s highlights:

1. New “Deltacron” COVID-19 Sub-Variant Could Be as Contagious as Measles
The new COVID-19 sub-variant, called “Deltacron” or “Stealth Omicron,” appears to be the most contagious strain yet. However, this does not necessarily mean there will be a dramatic spike in cases.

2. Not Over Yet: Researchers Identify “Deltacron” Hybrid COVID-19 Variant
“Deltacron,” a COVID-19 strain with genes from both the Delta and Omicron variants, appears to have been circulating since the beginning of the year.

3. Pfizer-BioNTech Submits Application for EUA for Second Booster Dose of COVID-19 Vaccine
The application is based on 2 Israeli studies for the additional shot for people 65 years and older.

4. Public Health Watch: ‘Substantial Burden’ of Influenza and RSV Deaths in US Prior to COVID-19 Pandemic
Findings of JAMA Network Open analysis reveal effects of interventions designed to prevent spread.

5. Pfizer CEO: A Fourth Dose of COVID-19 Vaccine is Needed
In a nationally televised interview, Pfizer Albert Bourla said it is necessary to fend off waning protection.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.